Introduction
Granulocyte-colony stimulating factor (G-CSF) has been administered to several hundred thousand related and unrelated donors of peripheral blood stem cells (PBSC) for cancer patients undergoing hematopoietic stem cell transplantation (HSCT). [1] [2] [3] Recently, questions have been raised about the safety of G-CSF administration to these individuals. 1, [4] [5] [6] [7] [8] [9] Herein, investigators with the Research on Adverse Drug Events and Reports (RADAR) project reviewed clinical literature on adverse events that occur when G-CSF is administered to healthy individuals, to patients with severe chronic neutropenia (SCN) and to cancer patients.
Methods
The RADAR project is a National Cancer Institute funded research program that identifies and disseminates clinical information on adverse drug reactions, with a particular emphasis on drugs used in hematology and oncology. 10, 11 RADAR investigators reviewed published articles on clinical and laboratory studies associated with potential serious adverse events reported with G-CSF administration to healthy donors, patients with SCN and cancer patients. A structured literature search was conducted using the PubMed MEDLINE interface. An initial search strategy was designed to be inclusive by using the intersection of the medical subject and keyword headings peripheral blood stem cell donors, granulocyte-colony stimulating factor, G-CSF and toxicity (n ¼ 1646) or peripheral blood stem cells (n ¼ 1714) or blood donors (n ¼ 177) or myelodysplasia (n ¼ 871) or acute leukemia (n ¼ 1627) or splenic rupture (n ¼ 20)). Primary consideration was focused on studies that included toxicity reports for healthy individuals who received G-CSF before PBSC harvesting. Additional studies addressed development of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or splenic rupture among healthy G-CSF-primed PBSC donors, patients with SCN or with cancer. Fifty-four studies met inclusion criteria. Most rejected articles were excluded because they lacked detailed clinical information on toxicity or were not written in English.
Results

Bone pain
In several studies in which G-CSF was administered to healthy individuals for PBSC harvesting, bone pain was reported as the most common adverse event by far. In one study reporting on 341 healthy donors who received 12 mg/kg/day of filgrastim for 3 days before leukapheresis, 84% of donors reported bone pain. 12 Data from a German multicenter study of 150 healthy donors reported similar results, with 80% of donors experiencing bone pain and headaches. 13 More recently, researchers in Italy reported bone pain in 52% of healthy donors who received 20 mg/kg/ day for 3 days. 14 The same Italian group further reported bone pain among 62% of healthy donors who received filgrastim in a retrospective study of healthy PBSC donors. 15 An analysis of adverse events among 94 healthy PBSC donors who received G-CSF in Japan reported bone pain in 71% of donors. 16 Each of these studies noted that bone pain was readily treated with common analgesics, such as acetaminophen or ibuprofen, and that the symptoms resolved within 4 days after discontinuation of G-CSF administration. Common associated symptoms included fatigue and fevers.
Autoimmune disorders
There have been reports of autoimmune events associated with G-CSF administration. Kroschinsky et al. 17 reported development of severe autoimmune hyperthyroidism in a patient who donated allogeneic PBSCs after receiving G-CSF. Another report described a breast cancer patient who developed reversible thyroid dysfunction with microsomal and thyroglobulin antibodies after receiving G-CSF following chemotherapy. 18 Two cases of reversible thyroid dysfunction were reported among cancer patients who received GM-CSF. 19 However, in two studies examining the effect of G-CSF on thyroid function in patients who received G-CSF after chemotherapy, no causal link between G-CSF and thyroid function or autoimmunity has been demonstrated. 20, 21 A review of the German Donor Registry did not identify an increase in autoimmune events among 3286 healthy donors who received G-CSF before PBSC harvest. 22 Splenic rupture Several studies evaluated effects of short-term administration of G-CSF on the spleen. Spleen size was studied in 84 healthy PBSC donors receiving G-CSF at a dose of 7.5 mg/ kg/day for 5 days. Average change noted was an increase of 11 mm in spleen length (a 10% increase in volume). [23] [24] [25] A second study showed that spleen size increased in 95% of donors with a mean length increase of 13%. The spleen size returned to baseline 10 days after G-CSF administration was complete. 23, 24 Eleven cases of splenic rupture have been reported in individuals who received G-CSF: four cases in healthy adult donors of PBSC and seven cases in persons with neutropenia or cancer ( Table 1) . [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Acute lung injury A few studies have evaluated the effects of G-CSF on pulmonary functions. One study evaluated serial measurements of arterial blood gas in 25 healthy donors who received 10 mg/kg of G-CSF for 5 days. These healthy donors exhibited arterial oxygenation decline, increased arterial carbon dioxide tension and loss of alveolar-arterial oxygen tension while receiving G-CSF. These results are indicative of significant gas exchange disturbance during G-CSF administration that resolved on discontinuation of the drug. 37 There has also been one case report of acute lung 
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Safety considerations of G-CSF administration CC Tigue et al injury in a healthy donor following PBSC mobilization with G-CSF. The 30-year-old man received 10 mg/kg/day of G-CSF and was diagnosed with acute lung injury on day 4 of G-CSF administration. 38 'In this case, only Interleukin (IL)-1b level was elevated, suggesting that that IL-1b was involved in the onset of G-CSF-related lung injury. Although potentially serious, G-CSF-related pulmonary toxicities are extremely rare.'
Vascular disorders, cardiac risks and death
Reports from the German Donor Registry provide information on vascular disorders among 3286 PBSC donors who received G-CSF. 22 In G-CSF-primed patients, three strokes and one myocardial infarction occurred between 3 months and 2.5 years after donation. One bone marrow donor developed a transverse myelitis (BrownSequard syndrome). Among 27 000 bone marrow donors and 23 000 PBSC donors evaluated by the European Blood and Marrow Transplant Registry, a small number of cardiac arrests occurred during bone marrow donation, but all patients were successfully resuscitated. Five procedurerelated deaths have also occurred, with no statistical difference between bone marrow and PBSC donors.
Acute myeloid leukemia/myelodysplasia Healthy PBSC donors. Three PBSC donors have been described who developed acute leukemia following stem cell mobilization ( Table 2) .
The RADAR project reported AML developing in two donors who underwent PBSC donation for sibling allogeneic HSCT.
3 AML developed 4 and 5 years, respectively, after G-CSF mobilization. The first patient had more than one immediate family member with AML and also developed a complex leukemic karyotype, suggesting a genetic predisposition. Following intensive chemotherapy, one patient died from AML and the second is in complete remission. Another group described a healthy PBSC donor who developed AML 14 months after stem cell mobilization with G-CSF before performing allogeneic HSCT for a brother with multiple myeloma. 39 Leukemia cells from the donor were positive for G-CSF receptors without karyotypic abnormalities and responded in vitro to G-CSF.
Single-site studies of adult PBSC donors have not shown late effects associated with short-term G-CSF therapy, with the longest follow-up now at 5 years [39] [40] [41] [42] [43] (Table 3) 1 reported that for bone marrow donors, 9 of 28 134 donors (0.032%) developed a hematological malignancy versus 5 of 16 431 donors (0.030%) who received G-CSF for PBSC collection. Although median follow-up times were not directly comparable between the two groups, if the incidence of AML in the general population is 5 cases per 100 000 patient-years, then 12 cases should have occurred. 48 The Center for International Blood and Marrow Transplant Research database contains information on more than 60 000 mostly adult sibling-donors and over 4000 unrelated National Marrow Donor Program donors who have received G-CSF. Of the unrelated donors who donated PBSC more than 1 year ago, 20 donors developed cancer and none developed leukemia or lymphoma. 49 This rate is consistent with the age-adjusted cancer rates. 50 Neonates with sepsis A 2-year follow-up study of 24 neonates treated with G-CSF for sepsis found no cases of leukemia. 51 One study of white cell subsets in nine donors, 1 year after donation, found no change in B, T and NK cells by flow cytometry analysis. 52 A mild decrease in monocytes was noted compared to the donor's baseline laboratory tests and when compared to 103 healthy normal volunteers. 52 
Table 2
Long-term evaluation of leukemia development among G-CSF treated blood stem cell donors Table 2 ). The Severe Chronic Neutropenia International Registry reported in 2006 that patients with SCN had a risk for progression to MDS/AML with G-CSF therapy of 2.9% per year after 6 years and 8.0% per year after 12 years. 53 This study compared the risk of MDS/AML between four subgroups of SCN patients. In the subgroup of SCN patients who received more than the median G-CSF dose but who were less responsive to treatment (29% of patients), 40% developed MDS/AML after 10 years. This rate was significantly greater than the 11% rate of MDS/ AML in the subgroup of SCN patients who were below the median dose of G-CSF but above median response level (a different 29% of patients). 53 In a second study, 11% of SCN patients and 19% of patients with Schwachman Diamond syndrome (also associated with increased propensity for leukemic transformation) developed MDS/AML after 20 years. 54 No patients with cyclic neutropenia or glycogen storage disease type 1b developed MDS/AML. As SCN patients are particularly susceptible to infection, patients with SCN had the highest exposure to G-CSF. Accordingly, the leukemia risk increased with the cumulative dose of G-CSF they received. 54 Patients with breast cancer Two large database studies of women with breast cancer have identified increased risks of AML following G-CSF administration (Table 3 ). The National Surgical Adjuvant Breast and Bowel Project reported the incidence of AML/MDS among breast cancer patients treated with different intensity chemotherapy regimens and the presence or absence of G-CSF support. They identified 1.01% of patients on the more intense chemotherapy regimen with G-CSF support that developed AML/MDS compared to 0.21% of patients who were treated with standard regimens without G-CSF support. 44 In the second study, analyses of women with breast cancer included in the Surveillance Epidemiology and End Results-Medicare database reported that after 4 or more years follow-up, AML/MDS occurred at double the rate in women who received G-CSF support versus those who did not receive this support (1.8 versus 0.7%, Po0.05). 45 This study controlled for all covariates including the type of chemotherapy, so that the risk of AML/MDS in patients who received G-CSF and those who did not could be appropriately compared.
Further comments
Our review of adverse events occurring after G-CSF administration to healthy individuals and patients with SCN or breast cancer has several important findings. Our main findings are that the primary short-term toxicities of G-CSF administration are bone pain, which is commonly noted, and rare instances of splenic rupture, cardiovascular events, acute lung injury and even death. With respect to other toxicities, including MDS/AML, the evidence supporting causality is unclear. In interpreting our findings, several factors should be considered.
First, laboratory investigations suggest that G-CSF administration may have leukemogenic potential in malignant cells, but these findings are nonspecific and can be found in nonmalignant cells. Nagler et al. 55 measured allele specific replication and aneuploidy in normal volunteer donors following G-CSF mobilization. These studies demonstrated that lymphocytes of G-CSF-mobilized donors displayed levels of allele-specific replication and aneuploidy similar to those observed in lymphocytes of leukemic patients. Although the loss of replication synchrony in the lymphocytes of G-CSF-mobilized donors returned to baseline after a few months, aneuploidy was still seen in a small number of donors up to 9 months after G-CSF administration. This result was also observed after G-CSF incubation in vitro and 5-azacytidine inhibited the effect in vitro. 1 Shapira et al. 56 identified similar findings using a double-stranded DNA relaxation technique. De novo synthesis of DNA in the white blood cell population of healthy donors increased with G-CSF administration, returning to baseline levels 1 to 2 months after completion of G-CSF therapy. Kaplinsky et al. 57 demonstrated that up to 0.6% of myeloid cells, but not purified CD34 þ stem progenitor cells, became tetraploid, indicating that G-CSF may induce alterations of chromosomal numbers in a small subset of mature myeloid cells in G-CSF-mobilized normal donors. Severe alterations in lymphocyte mitochondrial function have been demonstrated in circulating lymphocytes of normal PBSC donors treated with G-CSF. 58 Rutella et al. 58 found that collapse of mitochondrial transmembrane potential, hypergeneration of reactive oxygen species and genomic DNA fragmentation were induced by G-CSF. Another study evaluated gene expression profiles of healthy peripheral blood stem cell donors mobilized with G-CSF. 59 While expression of hundreds of genes changed within the first few days following G-CSF administration, these effects were not seen 2 months later. 59 Molecular studies in patients with AML and histories of SCN have revealed point mutations in the gene for the G-CSF receptor, suggesting that a truncated G-CSF receptor may increase the risk of leukemia. 60 However, the prevalence and pathogenicity of G-CSF receptor mutations in patients with SCN suggests that leukemic transformation is not inevitable in the presence of such mutations. 61 Second, with respect to autoimmune or vascular events, we have not identified any significant safety concerns with G-CSF administration. There are a large number of older PBSC donors now entering the pool to participate in reduced intensity conditioning regimens and these older donors may have a higher incidence of these complications as a baseline compared to younger bone marrow donors. In these studies, it will be impossible to identify clinical autoimmune or vascular events that directly result from G-CSF administration.
Third, splenic rupture following G-CSF administration is a known, but rare complication. Its incidence is estimated to be between 1 in 5000 and 1 in 10 000 donors. 62 The one predisposing factor is splenic trauma in the immediate post-HSCT donation period. Donors should be advised to avoid contact sports following HSCT donation.
Fourth, identification of an association between G-CSF use and development of AML/MDS does not prove causality. Patients with other cyclic or idiopathic neutropenia who have received extended courses of G-CSF therapy do not appear to have increased risks of AML/ MDS. G-CSF administration may extend the survival of patients with SCN or Schwachman Diamond syndrome long enough for AML/MDS to develop or G-CSF administration may shorten the time to progression to MDS/AML in patients who have an underlying genetic predisposition for developing this complication. Shared environmental exposures, heritable conditions and genetic susceptibility could have resulted in the development of AML in the three stem cell donors of siblings with AML or multiple myeloma who were reported to have developed this complication following G-CSF administration. HLAidentical siblings of patients with AML have a higher incidence of AML than the general population. 63 Therefore, identification of AML in case reports must be interpreted with caution.
Fifth, safety reports based on registry databases for PBSC donors have limitations. The European Group for Blood and Marrow Transplantation review was a voluntary survey and therefore some events may not have been identified. During the survey years, clinical practice shifted from bone marrow to peripheral blood stem cells as the primary stem cell source. The experience of the Center for International Blood and Marrow Transplant Research is more reliable, as reporting centers are required to submit follow-up blood test results. However, data were not obtained by a central monitoring group in direct contact with donors and hence, even in this database, some AML/MDS events may not have not been reported.
Comprehensive prospectively obtained registry data are needed to fully evaluate long-term safety concerns among healthy individuals who receive hematopoietic colonystimulating factors (Table 4 ) While the National Marrow Donor Program's prospective long-term registry is the best source of safety information for G-CSF-mobilized PBSC donors, more than 2000 normal donors will have to be followed for at least 10 years to detect a 10-fold increase in leukemia risk following G-CSF administration and detection of a smaller risk would require an even greater sample size. 48 The National Marrow Donor Program/Center for International Blood and Marrow Transplant Research is conducting a related donor safety study that will enroll several thousand North American donors of all ages over the next 5 years. Also, the Children's Oncology Group has initiated a prospective randomized study of G-CSFstimulated bone marrow collection compared to conventional marrow collection. The Children's Oncology Group will partner with the National Marrow Donor Program in the related donor safety study, using the developing national standard for long-term follow-up of normal Table 4 Number of hematologic malignancies reported in G-CSFprimed PBSC donors in major registries in the United States and Europe 
Conclusions
The most common short-term complication following G-CSF administration is bone pain, although on very rare occasions, splenic rupture or lung injury may occur. Concerns over AML/MDS development following G-CSF administration are based primarily on reports of increased rates of AML/MDS among women with breast cancer who received chemotherapy or patients with SCN who received G-CSF support. However, registry data from the United States and Europe have not identified any increased risk of AML/MDS when G-CSF has been administered to over 100 000 healthy individuals who donated PBSCs, although the median follow-up of these studies is less than 5 years. The clinical community should consistently provide information to long-term registries of G-CSF-primed donors of PBSCs.
